A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the administration of the study drug is
effective in increasing the chance of survival in patients with severe sepsis. Patients
entered into this study will be randomly assigned to one of two treatment groups. Patients in
each treatment group will be given either the study drug or placebo as a continuous infusion
directly into the bloodstream through a catheter placed in one of the patient's veins.
The study drug is an investigational drug that is still in development. It has been studied
in approximately 30 healthy subjects, approximately 30 patients with either kidney failure or
arthritis, and approximately 600 patients with severe sepsis. Patient participation in this
study will last for about one month.